ArticleInternational journal of surgery case reports2026
First successful radiofrequency ablation for papillary thyroid microcarcinoma in Indonesia: a case report.
Article in International journal of surgery case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Papillary thyroid microcarcinoma (PTMC) is the most common subtype of thyroid cancer, generally associated with a favorable prognosis. Radiofrequency ablation (RFA) is emerging as a minimally invasive alternative to surgery, particularly for patients unsuitable for active surveillance and surgery. This report presents the first documented case of RFA for PTMC in Indonesia. Case report: A 40-year-old woman presented with a palpable thyroid nodule on the right side of her neck. Thyroid ultrasound and thyroid core needle biopsy confirmed PTMC. The patient underwent RFA using a 5-mm probe tip and 50-Watt power, employing the "moving shot" technique. The procedure was successful, with no reported complications. Follow-up assessments showed a significant reduction in tumor volume of 95.38%, from 0.264 ml to 0.012 ml, with no signs of progression at 12 months. Discussion: RFA provides a minimally invasive alternative to active surveillance with advantages, giving patient definitive treatment. Compare to surgery, this treatment have advantage such as shorter procedure time, lower procedural costs, reduced blood loss, and preservation of thyroid function, leading to faster recovery. However, wider adoption in Indonesia remains limited by the need for trained operators and access to advanced ultrasonography equipment. Strengthening workforce training, improving infrastructure, and generating long-term outcome data are essential for broader implementation. Conclusion: This case highlights RFA as a safe and effective treatment for PTMC, particularly for patients who do not wish to undergo active surveillance management for low risk thyroid cancer. Further studies are necessary to assess its long-term efficacy and feasibility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.